For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230316:nRSP2811Ta&default-theme=true
RNS Number : 2811T Forterra plc 16 March 2023
16 March 2023
Forterra plc
Grant under Deferred Annual Bonus Plan
Forterra plc (the "Company") announces that, on 16 March 2023, share option
awards over ordinary shares of £0.01 each in the capital of the Company were
granted to Executive Directors under the Forterra plc Deferred Annual Bonus
Plan ("DABP") as follows:
Name of Director Number of shares over which the award is granted
Stephen Harrison 88,986
Ben Guyatt 64,542
Total 153,528
These awards represent the deferral into ordinary shares of part of the
Executive Directors' 2022 bonus entitlements under the rules of the Scheme.
No consideration was paid for the grant of the awards which are structured as
nominal cost options at an option exercise price of £0.01 per ordinary share.
The number of ordinary shares granted under the award has been calculated
using a share price of £2.05 being an average of the closing mid-market share
price for the five days commencing on 9 March 2023 being the date of
announcing the Company's 2022 results.
The awards will normally vest on 16 March 2026, subject to the participant
being an employee of the Company at that time. Once vested, the award shall
normally remain exercisable until the day before the tenth anniversary of the
date of grant. Further terms and conditions of the DABP are set out in the
Annual Report and Accounts.
The above notification is intended to satisfy the Company's obligations under
Article 19 of the Market Abuse Regulations.
Enquiries
Forterra plc: +44 (0) 1604 707 600
Ashley Thompson (Company Secretary)
FTI Consulting (public relations adviser to Forterra): +44 (0) 20 3727 1340
Richard Mountain
Nick Hasell
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCJFMRTMTTBBRJ